Skip to content

Benefit of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery

The Evaluation of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04384679
Enrollment
0
Registered
2020-05-12
Start date
2022-06-30
Completion date
2023-12-31
Last updated
2022-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nail Diseases

Keywords

Nails, Nail Surgery, Hemostasis, Potassium Ferrate

Brief summary

The purpose of this study is to assess the efficacy and safety of topical hemostatic powder containing hydrophilic polymer with potassium ferrate for bleeding control after nail surgical procedures

Interventions

DEVICEHydrophilic polymer and potassium ferrate powder

Application with pressure until hemostasis is achieved

Sponsors

Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years old * Patients scheduled for any type of nail surgical procedure * Willingness to participate in the study * Ability to understand all instructions in the English language

Exclusion criteria

* Failure to have nail surgery performed * Likely inability to comply with the study protocol or cooperate fully with the research team

Design outcomes

Primary

MeasureTime frameDescription
Time (in seconds) to bleeding cessation with hydrophilic polymer and potassium ferrate; time (in seconds) to bleeding cessation with direct pressure with sterile gauzeBaselineTime (in seconds) will be measured from application of intervention/nonintervention until bleeding cessation

Secondary

MeasureTime frameDescription
Number of participants with at least one adverse eventEnd of study (28 days)Adverse events will only include those that are determined to be related to the study device

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026